摘要
目的:探究靶向治疗联合化疗治疗原发性中枢神经系统淋巴瘤的临床效果及安全性。方法:选取2021年4—12月吉林省肿瘤医院收治的84例原发性中枢神经系统淋巴瘤患者为研究对象,按照随机数字表法分为对照组和研究组,各42例。对照组实施传统化疗,研究组在对照组基础上实施靶向治疗。对比两组临床疗效、不良反应发生率及生存期。结果:研究组治疗总有效率高于对照组(P=0.033)。研究组肾功能损害、胃肠道反应、口腔炎发生率低于对照组(P<0.05);两组血液毒性、神经毒性发生率对比,差异无统计学意义(P>0.05)。治疗后,研究组安全生存期长于对照组(P<0.001)。结论:临床采用靶向治疗联合化疗有利于提高原发性中枢神经系统淋巴瘤患者的临床疗效和生存期,且具有较高的安全性。
Objective:To investigate the clinical effect and safety of targeted therapy combined with chemotherapy in the treatment of primary central nervous system lymphoma.Methods:Eighty-four patients with primary central nervous system lymphoma admitted to Jilin Cancer Hospital from April to December 2021 were selected as study subjects,and were divided into the control group and the study group according to the method of randomized numerical table,each with forty-two cases.The control group implemented traditional chemotherapy,and the study group implemented targeted therapy on the basis of the control group.The clinical efficacy,incidence of adverse reactions and survival were compared between the two groups.Results:The total effective rate of treatment in the study group was higher than that in the control group(P=0.033).The incidence of renal function damage,gastrointestinal reaction and stomatitis in the study group was lower than that in the control group(P<0.05);the difference in the incidence of hematotoxicity and neurotoxicity between the two groups was not statistically significant when comparing the incidence of hematotoxicity and neurotoxicity in the two groups(P>0.05).The safe survival period of the study group was longer than that of the control group after treatment(P<0.001).Conclusion:The clinical use of targeted therapy combined with chemotherapy is conducive to improving the clinical efficacy and survival of patients with primary central nervous system lymphoma,and has a high degree of safety.
作者
于昊
李娜
左淑波
Yu Hao;Li Na;Zuo Shubo(Department of Lymphohematology,Jilin Cancer Hospital,Changchun 130012,Jilin Province,China;Fifth Department of Internal Medicine,Jilin Cancer Hospital,Changchun 130012,Jilin Province,China)
出处
《中外医药研究》
2024年第29期48-50,共3页
JOURNAL OF CHINESE AND FOREIGN MEDICINE AND PHARMACY RESEARCH
关键词
靶向治疗
化疗
中枢神经系统淋巴瘤
生存期
安全性
Targeted therapy
Chemotherapy
Central nervous system lymphoma
Survival
Safety
